BioCryst Pharmaceuticals, Inc. (BCRX) News & Overview - Discounting Cash Flows
BCRX
BioCryst Pharmaceuticals, Inc.
BCRX (NASDAQ)

BCRX's Business Model

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Sector & Industry Healthcare / Biotechnology
Website https://www.biocryst.com
CEO (Chief Executive Officer) Jon P. Stonehouse
Number of Employees
IPO date March 4, 1994

BCRX Latest News

Contact
CountryUS
Address4505 Emperor Boulevard
CityDurham
StateNC
Phone919 859 1302
Zip Code27703
Other Identifiers
CIK0000882796
ISINUS09058V1035
CUSIP09058V103
Open9.035
Previous Close9.06
Volume1.85 Mil.
Average Volume4.69 Mil.
Day’s Range8.85 – 9.055
52 Week Range6.02-11.31
MA (50)10.0088
MA (200)8.31765
Market Cap1.86 Bil.
Shares Out.209.2 Mil.
Earnings DateAug 04, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for BCRX

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us